Fig. 4 From: Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical studyMean baseline best-corrected visual acuity (BCVA) by the number of injections during the follow-up period. There is a moderate positive correlation between LogMAR baseline BCVA and the number of injections administered (r = 0.56). In other words, patients with worse baseline visual acuity required more intravitreal injections during the 24-week follow-up periodBack to article page